Drug intelligence / Profile preview

NCP03

Development stage: Preclinical
Lead developer: NextCell Pharma
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

NCP03 is an undisclosed preclinical-stage cell therapy candidate being developed by NextCell Pharma. It is based on the company's proprietary mesenchymal stromal/stem cell (MSC) platform, which utilizes a selection algorithm to identify and expand high-quality, potent donor-derived cells from umbilical cord tissue. NCP03 is currently in the discovery and preclinical development phases for undisclosed indications.

Beyond the preview

Go deeper on NCP03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCP03.

Explore the full profile